We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Strengthens Integrated Personalized Digital Care Platform
Read MoreHide Full Article
Key Takeaways
Hims & Hers grew subscribers to nearly 2.5 million in Q3 2025, expanding its digital-first care platform.
HIMS launched new testosterone options and a menopause specialty with personalized plans.
Hims & Hers introduced Labs, pairing biomarker tests with doctor-led action plans for proactive care.
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , is redefining healthcare delivery through a consumer-first, digital platform built around personalized, at-home care. The company generates the majority of its revenue through its online platform, where subscribers receive recurring shipments of treatments and services tailored to their needs. In the third quarter of 2025, subscribers grew to nearly 2.5 million, reflecting the continued scaling of a model centered on direct-to-consumer access, licensed provider oversight and recurring subscription relationships. The platform emphasizes personalization, with growing adoption of customized, multi-condition treatment plans supported by integrated provider networks and digital engagement tools.
Recent launches further expand this non-traditional care model. In men’s health, HIMS introduced a new testosterone category, including exclusive access to branded oral testosterone through a collaboration with Marius Pharmaceuticals, alongside compounded enclomiphene and combination therapies supported by at-home blood testing. On the women’s health side, Hims & Hers launched a menopause and perimenopause specialty, offering personalized treatment plans directed by licensed providers trained in life-stage care.
Most notably, Hims & Hers introduced Labs, a comprehensive whole-body diagnostic offering designed to provide proactive, data-driven health insights. By pairing biomarker testing with doctor-developed action plans and access to personalized treatments, the company is moving beyond reactive care toward a more preventive, connected healthcare experience delivered largely from home.
TDOC & MED Expanding Beyond Traditional Care Models
Teladoc Health, Inc. (TDOC - Free Report) continues to expand non-traditional care delivery through its integrated virtual care ecosystem. Teladoc Health recently enhanced its 24/7 Care service, enabling providers to treat a broader range of conditions, access real-time prescription benefit data, engage specialists instantly and proactively address preventive care gaps. Through its AI-enabled Prism platform and Clarity monitoring solution, Teladoc Health is also extending virtual oversight into hospital settings, adding workplace safety capabilities that use video and audio analytics to support early intervention.
Medifast, Inc. (MED - Free Report) delivers care through a coach-guided, direct-to-consumer model centered on its OPTAVIA lifestyle system. Medifast combines independent coaches, community support and scientifically developed products, with customers receiving products shipped directly to their homes. Through its collaboration with LifeMD, Medifast also provides eligible clients access to clinicians and GLP-1 medications when appropriate. With the introduction of Metabolic Synchronization, MED is expanding beyond weight loss to address metabolic health through structured, coach-supported programs grounded in clinical research.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have lost 71.8% over the past year, underperforming the industry’s decline of 40.2%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 1.4X is lower than the industry’s average of 3.5X and its three-year median of 2.6X. It carries a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 77.8% improvement from 2024.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #4 (Sell).
View the Zacks #1 Rank List
Image: Bigstock
Hims & Hers Strengthens Integrated Personalized Digital Care Platform
Key Takeaways
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , is redefining healthcare delivery through a consumer-first, digital platform built around personalized, at-home care. The company generates the majority of its revenue through its online platform, where subscribers receive recurring shipments of treatments and services tailored to their needs. In the third quarter of 2025, subscribers grew to nearly 2.5 million, reflecting the continued scaling of a model centered on direct-to-consumer access, licensed provider oversight and recurring subscription relationships. The platform emphasizes personalization, with growing adoption of customized, multi-condition treatment plans supported by integrated provider networks and digital engagement tools.
Recent launches further expand this non-traditional care model. In men’s health, HIMS introduced a new testosterone category, including exclusive access to branded oral testosterone through a collaboration with Marius Pharmaceuticals, alongside compounded enclomiphene and combination therapies supported by at-home blood testing. On the women’s health side, Hims & Hers launched a menopause and perimenopause specialty, offering personalized treatment plans directed by licensed providers trained in life-stage care.
Most notably, Hims & Hers introduced Labs, a comprehensive whole-body diagnostic offering designed to provide proactive, data-driven health insights. By pairing biomarker testing with doctor-developed action plans and access to personalized treatments, the company is moving beyond reactive care toward a more preventive, connected healthcare experience delivered largely from home.
TDOC & MED Expanding Beyond Traditional Care Models
Teladoc Health, Inc. (TDOC - Free Report) continues to expand non-traditional care delivery through its integrated virtual care ecosystem. Teladoc Health recently enhanced its 24/7 Care service, enabling providers to treat a broader range of conditions, access real-time prescription benefit data, engage specialists instantly and proactively address preventive care gaps. Through its AI-enabled Prism platform and Clarity monitoring solution, Teladoc Health is also extending virtual oversight into hospital settings, adding workplace safety capabilities that use video and audio analytics to support early intervention.
Medifast, Inc. (MED - Free Report) delivers care through a coach-guided, direct-to-consumer model centered on its OPTAVIA lifestyle system. Medifast combines independent coaches, community support and scientifically developed products, with customers receiving products shipped directly to their homes. Through its collaboration with LifeMD, Medifast also provides eligible clients access to clinicians and GLP-1 medications when appropriate. With the introduction of Metabolic Synchronization, MED is expanding beyond weight loss to address metabolic health through structured, coach-supported programs grounded in clinical research.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have lost 71.8% over the past year, underperforming the industry’s decline of 40.2%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 1.4X is lower than the industry’s average of 3.5X and its three-year median of 2.6X. It carries a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 77.8% improvement from 2024.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.